CJC-1295 no DAC (10mg vials)

CJC-1295 no DAC (10mg vials)

$100.00
Sale price  $100.00 Regular price 
Skip to product information
CJC-1295 no DAC (10mg vials)

CJC-1295 no DAC (10mg vials)

$100.00
Sale price  $100.00 Regular price 

CJC-1295 no DAC Kit

Save over 60%!

Cost per milligram
 
$4.44 – $5.85
Purity
99.43%
Certified Endotoxin-safe
Yes
Independently Tested
Yes

JP MOLECULAR LABS Id: WF03

Batch Id: CJ20250724

Research Studies

(for educational purposes only)

Study 1: An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS

Authors: Gilles Coppieters, Koen Deventer, Michaël Polet, Peter Van Eenoo, Péter Judák

Source: https://www.sciencedirect.com/science/article/abs/pii/S0731708522001479

Scientific Findings

This study presents a validated, antibody-free method for detecting GHRH analogues, including CJC-1295, in urine. The method utilizes ultrafiltration for sample preconcentration followed by nano-liquid chromatography-high-resolution mass spectrometry (nanoLC-HRMS/MS). This approach achieves low picogram-per-milliliter detection limits, offering a significant improvement over existing methods and enhancing the ability to detect misuse of these substances. The study highlights the method’s potential for extension to other peptides and in vitro generated metabolites for which antibodies are not available.

Plain English Interpretation

Scientists have developed a new, highly sensitive test to find specific performance-enhancing drugs, like CJC-1295, in urine. Instead of using traditional antibody-based methods, which can be complex and time-consuming, this new technique uses a simple filtration process to concentrate the urine sample. Then, a very precise machine separates and identifies the drug molecules. This makes it possible to detect even tiny amounts of these substances, making it harder for athletes to cheat. The new test is also adaptable, meaning it can be used to find new or modified drugs that may appear in the future.

 

Study 2: Advances in the detection of growth hormone releasing hormone synthetic analogs

Authors: Siham Memdouh, Ivana Gavrilović, Kelsey Ng, David Cowan, Vincenzo Abbate

Source: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3183

Scientific Findings

This study investigates the in vitro metabolism of four large GHRH synthetic analogs, including CJC-1295, in fortified human urine. The researchers identified nineteen major in vitro metabolites, which were then synthesized, purified, and characterized. A sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for their detection, achieving limits of detection of 1 ng/mL or less. This method provides a new tool for anti-doping agencies to detect the misuse of these substances.

Plain English Interpretation

Scientists have developed a new laboratory method to detect the use of performance-enhancing drugs like CJC-1295. They studied how the drug breaks down in urine and identified 19 different breakdown products. Based on this, they created a highly sensitive test that can find even very small traces of the drug or its byproducts. This makes it much harder for athletes to cheat by using these banned substances without getting caught.

 

Study 3: Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog

Authors: Lucie Jetté, Roger Léger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, Véronique Paradis, Pieter van Wyk, Khan Pham, Dominique P. Bridon

Source: https://academic.oup.com/endo/article/146/7/3052/2500187

Scientific Findings

This study investigated the in vitro properties of three maleimido derivatives of human growth hormone-releasing factor (hGRF)1-29, including CJC-1295. The researchers found that when conjugated to human serum albumin, all three derivatives, including CJC-1295, exhibited enhanced stability against the enzyme dipeptidylpeptidase-IV (DPP-IV). Furthermore, in a growth hormone (GH) secretion assay using cultured rat anterior pituitary cells, the albumin-conjugated peptides were found to be bioactive, demonstrating their ability to stimulate GH release in a controlled, in vitro environment.

Plain English Interpretation

Scientists created a modified version of a substance that tells the body to release growth hormone, called CJC-1295. They tested this new version in the lab and found that it was more stable and resistant to being broken down by enzymes in the body. They also showed that it could still trigger the release of growth hormone from pituitary cells in a petri dish. This means that the modified substance is not only more durable but also remains effective at its job, which could lead to longer-lasting effects in the body.

CJC-1295 no DAC Kit

Save over 60%!

Cost per milligram
 
$4.44 – $5.85
Purity
99.43%
Certified Endotoxin-safe
Yes
Independently Tested
Yes

JP MOLECULAR LABS Id: WF03

Batch Id: CJ20250724

Research Studies

(for educational purposes only)

Study 1: An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS

Authors: Gilles Coppieters, Koen Deventer, Michaël Polet, Peter Van Eenoo, Péter Judák

Source: https://www.sciencedirect.com/science/article/abs/pii/S0731708522001479

Scientific Findings

This study presents a validated, antibody-free method for detecting GHRH analogues, including CJC-1295, in urine. The method utilizes ultrafiltration for sample preconcentration followed by nano-liquid chromatography-high-resolution mass spectrometry (nanoLC-HRMS/MS). This approach achieves low picogram-per-milliliter detection limits, offering a significant improvement over existing methods and enhancing the ability to detect misuse of these substances. The study highlights the method’s potential for extension to other peptides and in vitro generated metabolites for which antibodies are not available.

Plain English Interpretation

Scientists have developed a new, highly sensitive test to find specific performance-enhancing drugs, like CJC-1295, in urine. Instead of using traditional antibody-based methods, which can be complex and time-consuming, this new technique uses a simple filtration process to concentrate the urine sample. Then, a very precise machine separates and identifies the drug molecules. This makes it possible to detect even tiny amounts of these substances, making it harder for athletes to cheat. The new test is also adaptable, meaning it can be used to find new or modified drugs that may appear in the future.

 

Study 2: Advances in the detection of growth hormone releasing hormone synthetic analogs

Authors: Siham Memdouh, Ivana Gavrilović, Kelsey Ng, David Cowan, Vincenzo Abbate

Source: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3183

Scientific Findings

This study investigates the in vitro metabolism of four large GHRH synthetic analogs, including CJC-1295, in fortified human urine. The researchers identified nineteen major in vitro metabolites, which were then synthesized, purified, and characterized. A sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for their detection, achieving limits of detection of 1 ng/mL or less. This method provides a new tool for anti-doping agencies to detect the misuse of these substances.

Plain English Interpretation

Scientists have developed a new laboratory method to detect the use of performance-enhancing drugs like CJC-1295. They studied how the drug breaks down in urine and identified 19 different breakdown products. Based on this, they created a highly sensitive test that can find even very small traces of the drug or its byproducts. This makes it much harder for athletes to cheat by using these banned substances without getting caught.

 

Study 3: Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog

Authors: Lucie Jetté, Roger Léger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, Véronique Paradis, Pieter van Wyk, Khan Pham, Dominique P. Bridon

Source: https://academic.oup.com/endo/article/146/7/3052/2500187

Scientific Findings

This study investigated the in vitro properties of three maleimido derivatives of human growth hormone-releasing factor (hGRF)1-29, including CJC-1295. The researchers found that when conjugated to human serum albumin, all three derivatives, including CJC-1295, exhibited enhanced stability against the enzyme dipeptidylpeptidase-IV (DPP-IV). Furthermore, in a growth hormone (GH) secretion assay using cultured rat anterior pituitary cells, the albumin-conjugated peptides were found to be bioactive, demonstrating their ability to stimulate GH release in a controlled, in vitro environment.

Plain English Interpretation

Scientists created a modified version of a substance that tells the body to release growth hormone, called CJC-1295. They tested this new version in the lab and found that it was more stable and resistant to being broken down by enzymes in the body. They also showed that it could still trigger the release of growth hormone from pituitary cells in a petri dish. This means that the modified substance is not only more durable but also remains effective at its job, which could lead to longer-lasting effects in the body.

Q: What are your advantages?

A: Honest management, service-oriented, affordable prices

You may also like